Webinars
March 13, 2025 | 11:00 - 11:30 AM ET
Join Trinity Life Sciences for a virtual demo where value, access and pricing experts Max Hunt and Andreia Ribeiro will demonstrate Trinity HTA Vision, our cloud-based dashboard with GenAI capabilities.It is not enough to know what the health technology assessment (HTA) decisions are and when they are made—with the landscape continually evolving, analogues and future impact cannot be judged by looking at decisions alone. Nuanced implications come from expert knowledge of countries/agencies, therapeutic areas and lifecycle stage.Discover the power of…
Sign Up Now
Webinars
March 5, 2025 | 12:00 - 12:30 PM ET
Are you ready to take a bite out of IC administration complexity?
Nothing demotivates a sales team like delayed or inaccurate incentive compensation (IC) calculations and payouts. While administering an IC plan may seem simple to outsiders, seasoned IC administrators know that’s not the case. It takes laser-focused attention to detail and timeliness to manage the constant flow of updates and ensure everything runs smoothly.
Join Trinity Life Sciences for a virtual lunch and learn where IC experts, Miles Scotcher…
Sign Up Now
Blog
Published February 5, 2025
How can pharma brands connect digital marketing experiences to achieve truly transformational customer engagement?
Brands that are leading the way demonstrate a complete grasp of fundamental digital marketing concepts and drive innovation in the ways that they engage customers. These brands maintain consistency in their message and interactions but tailor them to customer specific needs—and the innovation differentiates them in a market where many brands follow similar go-to-market strategies.
By exploring new ways of engagement in existing channels, they create…
Read Now
Webinars
February 25, 2025 | 1:00 - 1:45 PM ET
Two additional sessions will be offered:February 26 – 16:00 (UTC +8:00) – Asia/ShanghaiFebruary 26 – 15:00 CET – Europe/Berlin
There is no room for missteps along the journey to evaluate the viability of assets in early stages of development. When making go/no go decisions, many critical questions must be answered across the early asset lifecycle.Join a team of cross-functional experts from Trinity Life Sciences for a lively panel discussion on how to approach early commercial assessment with insight from various perspectives.…
Sign Up Now
Blog
Published January 28, 2025
Health equity continues to be a hot topic in the life sciences industry. ISPOR EU sessions addressed several key questions surrounding the impact of health equity on HTA decision-making, the methodologies that should be employed, and the opportunities and challenges of incorporating health equity into health technology assessment (HTA).
Ahead of ISPOR EU, Trinity’s HTA Vision team analyzed the impact of health equity on HTA agency behavior across six recent pharmaceutical launches and seven countries: Australia, Canada, England, France, Germany,…
Read Now
Blog
Published January 24, 2025
On January 20, 2025, CMS announced the set of fifteen drugs targeted for the second round of Maximum Fair Price (MFP) “negotiations” under IRA. With the outcomes of the first price “negotiations” announced only last August, the IRA MFP process is still in its early development and there remains uncertainty over how it will evolve – particularly in terms of the extent to which CMS will aim for true drug cost reductions vs. generating political capital via nominal “savings” on…
Read Now
Blog
Published January 21, 2025
Trinity recently presented a poster on climate resilience and environmental sustainability at ISPOR EU, titled “Attitudes and Perceptions on Environmental Sustainability Efforts in the Life Sciences Industry: A Cross-Sectional Survey from HEOR and Industry Professionals.” The poster discussed results from a recent survey conducted by our CREST (Climate Resilience and Environmental Sustainability at Trinity) team, which identified perceptions regarding life sciences industry efforts to tackle sustainability, particularly within HEOR, evidence generation and value communication strategy. We also published our new…
Read Now
Blog
Published January 17, 2025
One trend Trinity Life Sciences has observed and that was reinforced by stakeholders at ISPOR EU is the importance of evidence in healthcare decision-making. This trend was highlighted particularly in the context of joint clinical assessments (JCA) and health technology assessments (HTA). Trinity presented 11 posters at ISPOR EU, 6 of which focused on HTA and/or JCA.
JCA is an EU initiative intended to improve patient access to health technologies in Europe through a harmonized clinical HTA process. Beginning in January…
Read Now
Blog
Published January 10, 2025
Cell and gene therapies (CGTs) have ushered in a new era of medicine, offering patients transformative, even potentially curative solutions, with a single treatment. Despite the clinical promise, barriers to patient access remain given administration complexity, gaps in patient outcome evidence and high costs. As cell and gene therapies become available in new indications beyond oncology and rare pediatric diseases, developers of innovative therapies need to develop strategies targeting patients, providers and payers to overcome these challenges and promote access…
Read Now
Webinars
Available On Demand
Are you ready for the transition and change being forced on the pharmaceutical industry given the unprecedented Customer Relationship Management (CRM) changes announced by Veeva, Salesforce and IQVIA?
The status quo is not an option. Life science companies are being forced to evaluate the implications on their customer strategy and operations as the CRM is one piece of an increasingly integrated ecosystem. The CRM decision will influence commercial and medical data strategy and management, commercial interface architectures, marketing automation…
Watch Now
